AP02, an inhaled form of nintedanib being developed by Avalyn Pharma for idiopathic pulmonary fibrosis (IPF), was generally well tolerated and resulted in higher lung levels of the drug than oral nintedanib, according to findings from two Phase 1 trials. An oral formulation of nintedanib, sold as Ofev,…
Discussion
As my regular readers may remember, I am prescribed supplemental oxygen therapy. Pulmonary fibrosis makes it difficult to catch my breath during exertion. Long-distance walking has become difficult, going to the gym can be a challenge, and there are even days when it is simply hard to breathe. When…
Discussion
Raising awareness can take many forms, including education. September’s Pulmonary Fibrosis Awareness Month (PFAM) is an opportunity to educate not only the pulmonary fibrosis (PF) and interstitial lung disease (ILD) communities, but also the general public about the condition. When I was diagnosed with idiopathic pulmonary fibrosis…
Becoming educated and informed about PF is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your PF journey.
There is no cure for PF yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
